February 3, 2021 10:54 AM EST

Mutabilis receives CARB-X grant for 'nightmare bacteria' treatment; AbSci and Xyphos shake hands on discovery deal

Nicole DeFeudis

Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts

SV Health’s $269M dementia fund; Schrödinger lays off 7% of staff

GSK kicks off Blenrep relaunch plans with clearance from UK regulators

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?